Characterising individual response to mepolizumab treatment

被引：0
|
作者：
Jackson, David [1 ,2 ]
Price, Robert G. [3 ]
Yancey, Steven W. [4 ]
Buhl, Roland [5 ]
Wenzel, Sally [6 ]
机构：
[1] Kings Coll London, Guys Severe Asthma Ctr, Guys & St Thomas NHS Trust, London, England
[2] Kings Coll London, Sch Immunol & Microbial Sci, Asthma UK Ctr, London, England
[3] GSK, Biostat, Stevenage, Herts, England
[4] GSK, Resp Therapeut Area, Res Triangle Pk, NC USA
[5] Mainz Univ Hosp, Pulm Dept, Mainz, Germany
[6] Univ Pittsburgh, Asthma Inst, Pittsburgh, PA USA
来源：
EUROPEAN RESPIRATORY JOURNAL | 2020年 / 56卷
关键词：
Treatments; Asthma; -; management; Severe asthma;
D O I：
10.1183/13993003.congress-2020.2259
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
2259
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Treatment of Childhood Hypereosinophilic Syndrome with Mepolizumab
    Rose, S.
    Wistinghausen, B.
    Spencer, C.
    Vicencio, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [32] An evaluation of mepolizumab for the treatment of severe asthma
    Morjaria, Jaymin B.
    Emma, Rosalia
    Fuochi, Virginia
    Polosa, Riccardo
    Caruso, Massimo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (06) : 491 - 500
  • [33] MEPOLIZUMAB IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGITIS
    Philipson, B. S.
    Anderson, J.
    Brown, J. C.
    Busse, W. W.
    Cid, M.
    Gleich, G.
    Gross, W.
    Guillevin, L.
    Ortega, H.
    Jayne, D.
    Pagnoux, C.
    Savage, C.
    Weller, P.
    Wechsler, M. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 997 - 997
  • [34] Directions for Exercise Treatment Response Heterogeneity and Individual Response Research
    Hrubeniuk, Travis J.
    Bonafiglia, Jacob T.
    Bouchard, Danielle R.
    Gurd, Brendon J.
    Senechal, Martin
    INTERNATIONAL JOURNAL OF SPORTS MEDICINE, 2022, 43 (01) : 11 - 22
  • [35] Case of paradoxical adverse response to mepolizumab with mepolizumab-induced alopecia in severe eosinophilic asthma
    Nixon, Rodanthe
    Despiney, Raquel
    Pfeffer, Paul
    BMJ CASE REPORTS, 2020, 13 (02)
  • [36] Response to mepolizumab treatment in biologic-naive asthma patients and patients who received omalizumab
    Sasano, Hitoshi
    Harada, Norihiro
    Sato, Yoshihiko
    Sandhu, Yuuki
    Tanabe, Yuki
    Harada, Sonoko
    Jingo, Koichi
    Okuma, Tomoko
    Watanabe, Takayasu
    Kato, Yukari
    Nishimaki, Takayasu
    Abe, Sumiko
    Ueda, Shoko
    Goto, Ai
    Takeshige, Tomohito
    Matsuno, Kei
    Ito, Jun
    Nagaoka, Tetsutaro
    Atsuta, Ryo
    Takahashi, Kazuhisa
    RESPIROLOGY, 2023, 28 : 183 - 184
  • [37] Early treatment response may predict long-term mepolizumab benefit in severe asthma
    Kroes, Johannes A.
    Wiegman, Mirjam I.
    Van der Meer, Akke-Nynke
    Gijtenbeek, Rolof G. P.
    De Jong, Kim
    Zielhuis, Sander W.
    Van Roon, Eric N.
    Ten Brinke, Anneke
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [38] Predicting Individual Treatment Response Using EEG
    Vatinno, Amanda A.
    Schranz, Christian
    Ramakrishnan, Viswanathan
    AMERICAN JOURNAL OF OCCUPATIONAL THERAPY, 2021, 75
  • [39] Response to a case report: Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab
    Requena, Gema
    Roufosse, Florence
    Baylis, Lee D.
    Steinfeld, Jonathan
    RESPIROLOGY CASE REPORTS, 2021, 9 (02):
  • [40] RESPONSE TO TREATMENT OF INDIVIDUAL PATIENTS IN A DRUG TRIAL
    SUTHERLA.SS
    PHILIP, AE
    SUTHERLA.MS
    BRITISH JOURNAL OF PSYCHIATRY, 1969, 115 (529) : 1383 - &
12345